Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
72
RNA Quote, Financials, Valuation and Earnings
Last price:
$71.53
Seasonality move
:
32.33%
Day range:
$71.42 - $71.69
52-week range:
$21.51 - $71.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
450.42x
P/B ratio:
5.72x
Volume:
1.7M
Avg. volume:
7.8M
1-year change:
86.02%
Market cap:
$10.8B
Revenue:
$10.9M
EPS (TTM):
-$4.17
Analysts' Opinion
-
Consensus RatingAvidity Biosciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $74.00, Avidity Biosciences, Inc. has an estimated upside of 3.38% from its current price of $71.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $71.58.
Fair Value
-
According to the consensus of 14 analysts, Avidity Biosciences, Inc. has 3.38% upside to fair value with a price target of $74.00 per share.
RNA vs. S&P 500
-
Over the past 5 trading days, Avidity Biosciences, Inc. has overperformed the S&P 500 by 0.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Avidity Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avidity Biosciences, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Avidity Biosciences, Inc. reported revenues of $12.5M.
Earnings Growth
-
Avidity Biosciences, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Avidity Biosciences, Inc. reported earnings per share of -$1.27.
Enterprise value:
9B
EV / Invested capital:
4.63x
Price / LTM sales:
450.42x
EV / EBIT:
--
EV / Revenue:
429.34x
PEG ratio (5yr expected):
-0.39x
EV / Free cash flow:
-15.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$17.5M
Return On Assets:
-33.66%
Net Income Margin (TTM):
-2634.59%
Return On Equity:
-37.47%
Return On Invested Capital:
-37.09%
Operating Margin:
-1513.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.1M | $10.1M | $20.9M | $2.3M | $12.5M | |
| Gross Profit | $6.1M | $7.5M | $17.5M | $1.6M | $11.4M | |
| Operating Income | -$222.1M | -$324.7M | -$612.5M | -$98.1M | -$188.8M | |
| EBITDA | -$218.1M | -$322M | -$609.1M | -$97.4M | -$187.8M | |
| Diluted EPS | -$2.99 | -$2.90 | -$4.17 | -$0.65 | -$1.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $422M | $414.5M | $555.5M | $1.6B | $2B | |
| Total Assets | $425.9M | $430.5M | $573.2M | $1.6B | $2.1B | |
| Current Liabilities | $22.4M | $42.7M | $48.7M | $91.3M | $169.9M | |
| Total Liabilities | $31M | $53.6M | $55.7M | $137.4M | $247.9M | |
| Total Equity | $394.9M | $377M | $517.5M | $1.5B | $1.9B | |
| Total Debt | $977K | $8.2M | $7M | $3.8M | $46M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$174.8M | -$184.5M | -$580.5M | -$65.6M | -$156.2M | |
| Cash From Investing | -$188.9M | -$739M | -$309.4M | -$482.4M | -$587.9M | |
| Cash From Financing | $305.6M | $1.2B | $869.8M | $342.5M | $850.4M | |
| Free Cash Flow | -$179M | -$188.5M | -$592.3M | -$67.3M | -$156.9M | |
RNA
Sector
Market Cap
$10.8B
$28.4M
Price % of 52-Week High
99.72%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-13.73%
-1.32%
1-Year Price Total Return
86.02%
-22.19%
Beta (5-Year)
0.904
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$71.38
200-day SMA
Buy
Level
$40.50
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$70.83
Relative Strength Index (RSI14)
Buy
Level
77.05
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-14.7059
50-day SMA
Buy
Level
$59.63
MACD (12, 26)
Buy
Level
3.04
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.5726)
Buy
CA Score
(Annual)
Level (-0.2832)
Buy
Beneish M-Score
(Annual)
Level (-3.3486)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.413)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, RNA has received 3 Buy ratings 11 Hold ratings, and 0 Sell ratings. The RNA average analyst price target in the past 3 months is $74.00.
-
Where Will Avidity Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avidity Biosciences, Inc. share price will rise to $74.00 per share over the next 12 months.
-
What Do Analysts Say About Avidity Biosciences, Inc.?
Analysts are divided on their view about Avidity Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avidity Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Avidity Biosciences, Inc.'s Price Target?
The price target for Avidity Biosciences, Inc. over the next 1-year time period is forecast to be $74.00 according to 14 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is RNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avidity Biosciences, Inc. is a Hold. 11 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RNA?
You can purchase shares of Avidity Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avidity Biosciences, Inc. shares.
-
What Is The Avidity Biosciences, Inc. Share Price Today?
Avidity Biosciences, Inc. was last trading at $71.53 per share. This represents the most recent stock quote for Avidity Biosciences, Inc.. Yesterday, Avidity Biosciences, Inc. closed at $71.58 per share.
-
How To Buy Avidity Biosciences, Inc. Stock Online?
In order to purchase Avidity Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RNA
Sector
P/E ratio
--
23.66x
PEG ratio
-0.39x
-0.01x
P/B ratio
5.72x
1.84x
Price / LTM sales
450.42x
1.60x
Growth Metrics
RNA
Sector
Revenue growth
434.03%
4.85%
Earnings growth
-94.11%
11.15%
Revenue (5-year growth)
36.27%
6.45%
Earnings forecast
-$1.10
-$0.20
Profitability
RNA
Sector
Profitability FY 2024
$8.1M
$3.6M
Return on invested capital
-37.09%
-30.98%
Return on assets
-33.66%
-27.62%
Return on equity
-37.47%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
9
Balance Sheet
RNA
Sector
Total cash
$1.9B
$27.2M
Short term investments
$1.3B
$25.7M
Total assets
$1.6B
$79.9M
Long term debt
$46M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
